Pulmonx (LUNG) Other Non-Current Liabilities (2020 - 2022)
Pulmonx's (LUNG) quarterly Other Non-Current Liabilities came in at $179000.0 in Q2 2022, little changed on a QoQ basis from $179000.0 in Q1 2022.
Pulmonx (LUNG) Other Non-Current Liabilities (2020 - 2022) Analysis & Trends
Pulmonx (LUNG) has 3 years of Other Non-Current Liabilities data on file, last reported at $179000.0 in Q2 2022.
- On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $179000.0 in Q2 2022; TTM through Jun 2022 was $179000.0, a N/A change from a year earlier, with the FY2021 full-year figure at $179000.0, changed N/A from the prior year.
- Other Non-Current Liabilities for Q2 2022 stood at $179000.0, roughly flat from $179000.0 in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for LUNG reached as high as $1.9 million in Q3 2020 and fell as low as $179000.0 in Q4 2021.
- Historically, Other Non-Current Liabilities has averaged $598250.0 across 3 years, with a median of $179000.0 in 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Pulmonx | 49.94 Mn | -19.81 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 179,000.00 |
| Mar 31, 2022 | 179,000.00 |
| Dec 31, 2021 | 179,000.00 |
| Sep 30, 2020 | 1.86 Mn |